January 20, 2016

Reuters is reporting that Vice President Joe Biden, who President Barack Obama has tasked with working to cure cancer, announced Tuesday that the Food and Drug Administration, alongside drug companies, would work to speed up approval of new combination therapy proposals. Biden said he met with the head of the FDA and three drug companies at his home to discuss how to provide more patients with drugs that can help them. (Reuters)

January 19, 2016
Oncology therapy patients at the specialty pharmacy now receive a Therapy Comfort Care Kit that contains items to make the therapy process less uncomfortable. 
January 15, 2016

Challenges to growth include investor wariness as a result of the low cost-to-benefit ratio when it comes to drugs treating pancreatic cancer, given the poor prognosis and dominance of a generic treatment. 

January 14, 2016

AFPE supports training, research and graduate education in pharmaceutival science, pharmacology and toxicology, pharmaceuticals, pharmacotherapy and medicinal and pharmaceutical chemistry, among other.

January 13, 2016

The specialty pharmacy has promoted two of its own to newly created positions that reflect a growing company, BioPlus said. 

January 7, 2016

Diplomat Pharmacy has published a report looking back at the number of drug approvals in 2015, many of which were for specialty medications. 

January 6, 2016

This group of drugs made up 47% of all approvals in 2015, making it the year that the most orphan drugs were approved in FDA history. 

December 23, 2015

The Food and Drug Administration on Monday approved Actelion Pharmaceutivals' Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension.

December 18, 2015

Diplomat Pharmacy has been awarded full Specialty Pharmacy by URAC since 2012.

December 18, 2015

AstraZeneca on Thursday announced that it has agreed to acquire a majority stake in privately-held, cancer-drug developer Acerta Pharma for $4 billion. (New York Times)

December 17, 2015

The Rare Disease COE is custom-built to serve the unique needs of rare-disease populations, with a team of specialists who establish one-on-one relationships with patients.

December 16, 2015

CVS Health shared five key innovations that are delivering value both to patients and strategic partners in growing its retail pharmacy business at its annual analyst day. 

December 15, 2015

The Food and Drug Administration has approved Teva and Eagle Pharmaceuticals’  Bendeka (bendamustine hydrochloride), an injection and 10-minute infusion formulation. 

December 15, 2015

Significantly, 53% of employers have added new coverage and utilization restrictions for specialty pharmacy, such as requiring prior authorization or limiting quantities based on clinical evidence.

December 15, 2015

The Food and Drug Administration approved the new multiple myeloma drug four months ahead of the date of its Priority Review. 

December 4, 2015

According to the report, from 2009 to 2014, branded and generic specialty sales in the United States grew at an annual compound growth rate of 12%, with a dominant force being oncology. 

December 2, 2015

According to an Associated Press report published in the New York Times, a bipartisan Senate Finance committee report found that Gilead Sciences, maker of hepatitis C treatments Harvoni and Sovaldi, chose to price Sovaldi at $1,000 a pill ($84,000 for a course of treatment) despite evidence that a lower price would allow more people to take advantage of the treatment. Gilead rejected the committee’s conclusions, noting that it “responsibly and thoughtfully priced Sovaldi and Harvoni,” as lawmakers point to this case as a cautionary tale for other expensive treatments. (New York Times)

December 2, 2015

The Detroit Free Press Top Workplaces are based solely on employee feedback. In Michigan this year, more than 61,000 employees filled out surveys.  

November 30, 2015

Takeda’s Ninlaro is a treatment for patients with multiple myeloma who have had at least one prior therapy. 

November 30, 2015

The combined company’s revenue for the 12 months ended June 30 exceeded $800 million. 

November 24, 2015

Eli Lilly and Co.’s Petrazza in a trial extended the lives of patients who took the drug in combination with two forms of chemotherapy to 11.5 months. 

November 20, 2015

The average annual cost of a specialty medication used on a chronic basis exceeded $53,000 in 2013, which is more than the median U.S. household income, AARP noted.